1470 Estimation of Circulating Svcam-1, Seselectin and Sil2R in Children with Acute Lymphoblastic Leukemia

Abstract

Clotting screen: Normal-11 patients (79%), Deranged-2 patients (15%), Not performed-1 patient (7%). Staging: Pretext II-7 patients (51%), Pretext III-3 patients (21%), Pretext IV-3 patients (21%), Awaited-1 patient (7%). Diagnosis: Non Metastatic Hepatoblastoma-Standard risk 8 patients (58%) and High risk 3 patients (21%),Metastatic Hepatoblastoma 3 patients (21%). Pre-op chemotherapy: SIOPEL one-1 patient (7%),SIOPEL three-8 patients (57%), SIOPEL four-5 patients (36%). Chemotherapy treatment: On time-11 patients (79%), Delayed-3 patients (21%). Timing of surgery from initial diagnosis: 10 patients (70%) 2-4 months, 2 patients (15%) 4-5 months, 2 patients (15%) awaiting. Type of Surgery: Orthotopic liver transplant-3 patients (21%), Partial hepatectomy-9 patients (64%), Awaiting-2 patients (15%). Associated syndrome: Present (Beckwith-Wiedemann syndrome, Fanconi syndrome and 2 parents had familial polyposis coli)-4 patients (30%), Absent-10 patients (70%). Post-op chemotherapy: SIOPEL one-1 patient (7%), SIOPEL three-7 patients (50%), SIOPEL four-3 patients (21%), Not applicable-1 patient (7%), Awaited-2 patients (15%). Complications of chemotherapy: Yes (Hearing loss)-3 patients (21%), Nil-11 patients (79%). Outcome: Remission-10 patients (70%), Died-2 patients (15%), Undergoing treatment-2 patients (15%). Conclusions Incidence Overall 0.02 per 100,000 versus 2 per 100,000 worldwide. Platelet count: Abnormally high in 57% patients. Survival rate: Overall 83.5% (10/12) versus 70% worldwide.